The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

Researchers found cardiovascular drugs were associated with 24.7 percent of all medication errors, followed by antibiotics at 19.1 percent, electrolytes at 11.3 percent, endocrine drugs at 8.8 percent ...

Despite major advances in oncology, drug resistance remains one of the principal obstacles to achieving durable responses and cure in cancer patients. Both ...